GlassScriptPhysician profile
Peter Addison Knoll
NPI 1457669525
$13,518.47
in general payments reported to CMS, 2019-2025
13 companies · $3,041 in 2025
The $3,041 reported for 2025 was more than what 76% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $110 · 2021: $257 · 2022: $3,975 · 2023: $553 · 2024: $3,354 · 2025: $3,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,284 · Food and Beverage: $2,567 · Education: $96.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,284.14 |
| Food and Beverage | $2,567.23 |
| Education | $96.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $11,733.01 | 2019-2025 | Persona, Rosa, Arcos |
| Stryker Corporation | $1,198.43 | 2019-2024 | Mako |
| Lima USA, INC. | $167.50 | 2021 | |
| Depuy Synthes Sales INC. | $117.44 | 2019-2023 | Inhance |
| Ethicon US, LLC | $76.92 | 2020-2025 | Stratafix, Dermabond Prineo, Vistaseal |
| Heron Therapeutics, INC. | $62.45 | 2025 | Zynrelef |
| Avanos Medical | $37.21 | 2020 | |
| Amgen INC. | $26.46 | 2024 | Evenity, Prolia |
| Vertex Pharmaceuticals Incorporated | $24.51 | 2025 | |
| Innovation Technologies INC | $24.16 | 2025 | Irrisept |
| Ferring Pharmaceuticals INC. | $23.89 | 2019 | |
| Polynovo North America LLC | $13.79 | 2025 | Novosorb Btm |
| Smith+Nephew, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Knoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.